- Advertise
- OLE Scientific Interchange Workshops
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
tgen | Strategic Alliance Partners
Latest from tgen
Dr. Mikhael on Remaining Challenges in High-Risk Multiple Myeloma
November 24, 2020
Video
Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.
Dr. Mikhael on Unmet Needs in Triple-Class Refractory Multiple Myeloma
November 19, 2020
Video
Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.
Dr. Jeffrey Trent on the Melanoma Dream Team
July 27, 2015
Video
Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.
TGen and George Mason University Announce Precision Medicine Alliance for Patients With Serious Illnesses
May 24, 2014
Article
$12 million in grants pursued by TGen-George Mason Molecular Medicine Alliance, leveraging institutes' expertise in genomics and proteomics.
Dr. Ramanathan on Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
April 30, 2014
Video
Ramesh K. Ramanathan, MD, describes a phase II study that analyzed gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.
Nab-Paclitaxel Boosts Survival in Pancreatic Cancer
December 04, 2013
Article
The addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.